title: The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
abstract: The aim of this study was to prospectively evaluate the impact of early bone marrow response on complete remission (CR) rate and long-term outcome in adults with acute myeloid leukemia. Bone marrow cytology was assessed on day 6 of induction treatment in 164 patients, revealing the presence of ≥5% blasts in 61 cases. In this subgroup the CR rate was significantly lower compared to the remaining patients (P < 0.00001) resulting in decrease of the overall survival (P = 0.002). Persistence of ≥5% blasts in bone marrow on day 6 of induction is an easily available surrogate marker to be used for treatment decisions.
authors.affiliation: Oddzial Hematologiczny, SPZOZ ZSM, Karola Miarki Str 40, Chorzow, Poland. sgrosicki@wp.pl
authors.forename: Sebastian
authors.initials: S
authors.lastname: Grosicki
authors.forename: Jerzy
authors.initials: J
authors.lastname: Holowiecki
authors.forename: Sebastian
authors.initials: S
authors.lastname: Giebel
authors.forename: Slawomira
authors.initials: S
authors.lastname: Kyrcz-Krzemien
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Kuliczkowski
authors.forename: Marek
authors.initials: M
authors.lastname: Kielbinski
authors.forename: Aleksander B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: Beata
authors.initials: B
authors.lastname: Piatkowska-Jakubas
authors.forename: Andrzej
authors.initials: A
authors.lastname: Hellmann
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Wierzbowska
authors.forename: Beata
authors.initials: B
authors.lastname: Stella-Holowiecka
authors.forename: Barbara
authors.initials: B
authors.lastname: Zdziarska
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Calbecka
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000473:pathology; D002452:Cell Count; D015331:Cohort Studies; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D011044:Poland; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers